121 related articles for article (PubMed ID: 28985947)
1. Induction of the chromosomal translocation t(14;18) by targeting the BCL-2 locus with specific binding I-125-labeled triplex-forming oligonucleotides.
Dahmen V; Schmitz S; Kriehuber R
Mutat Res Genet Toxicol Environ Mutagen; 2017 Nov; 823():58-64. PubMed ID: 28985947
[TBL] [Abstract][Full Text] [Related]
2. Iodine-125-labeled DNA-Triplex-forming oligonucleotides reveal increased cyto- and genotoxic effectiveness compared to Phosphorus-32.
Dahmen V; Pomplun E; Kriehuber R
Int J Radiat Biol; 2016 Nov; 92(11):679-685. PubMed ID: 27022855
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic effects and specific gene expression alterations induced by I-125-labeled triplex-forming oligonucleotides.
Dahmen V; Kriehuber R
Int J Radiat Biol; 2012 Dec; 88(12):972-9. PubMed ID: 22694342
[TBL] [Abstract][Full Text] [Related]
4. Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for anti-gene radiotherapy.
Panyutin IG; Winters TA; Feinendegen LE; Neumann RD
Q J Nucl Med; 2000 Sep; 44(3):256-67. PubMed ID: 11105589
[TBL] [Abstract][Full Text] [Related]
5. DNA damage produced by 125I-triplex-forming oligonucleotides as a measure of their successful delivery into cell nuclei.
Panyutin IV; Sedelnikova OA; Bonner WM; Panyutin IG; Neumann RD
Ann N Y Acad Sci; 2005 Nov; 1058():140-50. PubMed ID: 16394133
[TBL] [Abstract][Full Text] [Related]
6. Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus.
Dyer MJ; Lillington DM; Bastard C; Tilly H; Lens D; Heward JM; Stranks G; Morilla R; Monrad S; Guglielmi P; Kluin-Nelemans JC; Hagemeijer A; Young BD; Catovsky D
Leukemia; 1996 Jul; 10(7):1198-208. PubMed ID: 8684002
[TBL] [Abstract][Full Text] [Related]
7. Pseudonegative BCL2 protein expression in a t(14;18) translocation positive lymphoma cell line: a need for an alternative BCL2 antibody.
Masir N; Campbell LJ; Jones M; Mason DY
Pathology; 2010 Apr; 42(3):212-6. PubMed ID: 20350212
[TBL] [Abstract][Full Text] [Related]
8. DNA structural basis for fragility at peak III of BCL2 major breakpoint region associated with t(14;18) translocation.
Javadekar SM; Yadav R; Raghavan SC
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):649-659. PubMed ID: 29246583
[TBL] [Abstract][Full Text] [Related]
9. Sequence-specific gene cleavage in intact mammalian cells by 125I-labeled triplex-forming oligonucleotides conjugated with nuclear localization signal peptide.
Sedelnikova OA; Karamychev VN; Panyutin IG; Neumann RD
Antisense Nucleic Acid Drug Dev; 2002 Feb; 12(1):43-9. PubMed ID: 12022689
[TBL] [Abstract][Full Text] [Related]
10. Targeting the human mdr1 gene by 125I-labeled triplex-forming oligonucleotides.
Sedelnikova OA; Panyutin IG; Luu AN; Reed MW; Licht T; Gottesman MM; Neumann RD
Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):443-52. PubMed ID: 11198928
[TBL] [Abstract][Full Text] [Related]
11. Antigene radiotherapy: targeted radiodamage with 125i-labeled triplex-forming oligonucleotides.
Panyutin IG; Sedelnikova OA; Karamychev VN; Neumann RD
Ann N Y Acad Sci; 2003 Dec; 1002():134-40. PubMed ID: 14751831
[TBL] [Abstract][Full Text] [Related]
12. Expression and replication timing patterns of wildtype and translocated BCL2 genes.
Sun Y; Wyatt RT; Bigley A; Krontiris TG
Genomics; 2001 Apr; 73(2):161-70. PubMed ID: 11318606
[TBL] [Abstract][Full Text] [Related]
13. Variation in BCL2 protein expression in follicular lymphomas without t(14;18) chromosomal translocations.
Masir N; Jones M; Abdul-Rahman F; Florence CS; Mason DY
Pathology; 2012 Apr; 44(3):228-33. PubMed ID: 22406486
[TBL] [Abstract][Full Text] [Related]
14. Modulated binding of SATB1, a matrix attachment region protein, to the AT-rich sequence flanking the major breakpoint region of BCL2.
Ramakrishnan M; Liu WM; DiCroce PA; Posner A; Zheng J; Kohwi-Shigematsu T; Krontiris TG
Mol Cell Biol; 2000 Feb; 20(3):868-77. PubMed ID: 10629043
[TBL] [Abstract][Full Text] [Related]
15. Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for antigene radiotherapy.
Sedelnikova OA; Luu AN; Karamychev VN; Panyutin IG; Neumann RD
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):391-6. PubMed ID: 11173132
[TBL] [Abstract][Full Text] [Related]
16. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.
Carbone GM; McGuffie E; Napoli S; Flanagan CE; Dembech C; Negri U; Arcamone F; Capobianco ML; Catapano CV
Nucleic Acids Res; 2004; 32(8):2396-410. PubMed ID: 15121897
[TBL] [Abstract][Full Text] [Related]
17. Transcription dependence of chromosomal gene targeting by triplex-forming oligonucleotides.
Macris MA; Glazer PM
J Biol Chem; 2003 Jan; 278(5):3357-62. PubMed ID: 12431993
[TBL] [Abstract][Full Text] [Related]
18. An efficient antigene activity and antiproliferative effect by targeting the Bcl-2 or survivin gene with triplex forming oligonucleotides containing a W-shaped nucleoside analogue (WNA-βT).
Taniguchi Y; Sasaki S
Org Biomol Chem; 2012 Oct; 10(41):8336-41. PubMed ID: 22987068
[TBL] [Abstract][Full Text] [Related]
19. Targeting bcl-2 by triplex-forming oligonucleotide--a promising carrier for gene-radiotherapy.
Shen C; Rattat D; Buck A; Mehrke G; Polat B; Ribbert H; Schirrmeister H; Mahren B; Matuschek C; Reske SN
Cancer Biother Radiopharm; 2003 Feb; 18(1):17-26. PubMed ID: 12667305
[TBL] [Abstract][Full Text] [Related]
20. BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2.
Gollub W; Stassek B; Huckhagel T; Bernd HW; Krokowski M; Merz H; Feller AC; Thorns C
Anticancer Res; 2009 Nov; 29(11):4649-55. PubMed ID: 20032416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
